Products
Upinitatug Biosimilar Monoclonal Antibody (NaPi2b) for Research
Cat No.: GMP-Bios-INN-1443
Anti-SLC34A2 therapeutic antibody (Pre-made Upinitatug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Upinitatug (formerly known as upifitamab) is a humanized monoclonal antibody targeting SLC34A2 (sodium-dependent phosphate transporter type 2B, NaPi-IIb). It is developed by Mersana Therapeutics for ovarian cancer and non-small cell lung cancer in Phase III development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1443-1mg | 1mg | 3090 |
| GMP-Bios-INN-1443-10mg | 10mg | |
| GMP-Bios-INN-1443-100mg | 100mg | |
| GMP-Bios-INN-1443-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Upinitatug biosimilar, Whole mAb, Anti-SLC34A2 Antibody: Anti-SLC34A2/Sodium-dependent phosphate transport protein 2B/Sodium-phosphate transport protein 2B/Na(+)-dependent phosphate cotransporter 2B therapeutic antibody |
| INN Name | Upinitatug |
| Target | SLC34A2 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2019 |
| Year Recommended | 2020 |
| Companies | Mersana Therapeutics |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Non-small cell lung cancer;Ovarian cancer |
| Production | na |
| Development Tech | na |
